which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

which is currently under FDA review. Approval for a monthly IV dose of Leqembi is also being sought. The Alzheimer’s Drug Discovery Foundation (ADDF) also welcomed the approval, saying it would ...

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi ... The analysis was based on deaths reported in the FDA Adverse Event Reporting System (FAERS), which states on its ...

Cassava Sciences' Alzheimer's drug simufilam failed to meet primary ... subset could be put forward that would persuade the FDA simufilam deserves another shot at proving itself?

This is unnecessary pain and suffering that could be avoided if we were simply allowed to keep patients on the FDA-approved medication that was appropriate in the first place. Alzheimer’s ...

The United Kingdom medicines authority approved the Alzheimer ... highlighted when the FDA initially denied approval of donanemab. The agency questioned the drug’s long term safety, noting ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug ... in a late study for Alzheimer’s disease (AD).